Emergence and evolution of TP53 mutations are key features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with lenalidomide.
Lodé L, Ménard A, Flet L, Richebourg S, Loirat M, Eveillard M, Le Bris Y, Godon C, Theisen O, Gagez AL, Cartron G, Commes-Maerten T, Villemagne B, Luycx O, Godmer P, Pellat-Deceunynck C, Soussi T, Béné MC, Delaunay J, Peterlin P.
Lodé L, et al. Among authors: gagez al.
Haematologica. 2018 Apr;103(4):e143-e146. doi: 10.3324/haematol.2017.181404. Epub 2017 Dec 21.
Haematologica. 2018.
PMID: 29269520
Free PMC article.
No abstract available.